Details

---

• Manufacturer: Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

• Registration in Malaysia: MAL18016005AZ

Content

• Active Ingredients: Each film-coated tablet contains 10 mg empagliflozin and 5 mg linagliptin.

• Formulation: Pale yellow, arc triangular, flat-faced, bevel-edged tablets.

• Manufacturer: Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.

• Registration in Malaysia: MAL18016005AZ.

Indications

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults when treatment with both empagliflozin and linagliptin is appropriate.

• Combination Therapy: For patients inadequately controlled on monotherapy with either empagliflozin or linagliptin.

• Not for: Use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Instructions for Use

• Dosage: Start with 10 mg empagliflozin/5 mg linagliptin once daily. The dose may be increased to 25 mg/5 mg once daily if additional glycemic control is needed and the patient tolerates the medication.

• Administration: Take with or without food, swallowed whole with water.

• Renal Function: Assess renal function before initiating treatment. Not recommended for patients with an eGFR less than 30 mL/min/1.73 m².

• Missed Dose: If a dose is missed, take it as soon as possible unless it's almost time for the next dose. Do not double doses.

• Temporary Interruption: Withhold for at least 3 days prior to major surgery or procedures associated with prolonged fasting.